88 related articles for article (PubMed ID: 31072748)
1. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
2. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
4. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
Grimm MO; Oya M; Choueiri TK; Motzer RJ; Schmidinger M; Quinn DI; Gravis-Mescam G; Verzoni E; Van den Eertwegh AJM; di Pietro A; Mariani M; Wang J; Thomaidou D; Albiges L
Eur Urol; 2024 Jan; 85(1):8-12. PubMed ID: 37852850
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma.
Wang HT; Xia M
Medicine (Baltimore); 2019 Jan; 98(1):e13779. PubMed ID: 30608388
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA; Hariharan S; Chudnovsky A; Ching KA; Mu XJ; Mariani M; Robbins PB; Huang B; di Pietro A; Albiges L
ESMO Open; 2021 Jun; 6(3):100101. PubMed ID: 33901870
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K; Osawa T; Kojima T; Hara T; Eto M; Takeuchi A; Nakai Y; Ueda K; Ozawa M; Uemura M; Ohba K; Tamura K; Shindo T; Nakagomi H; Takahashi A; Anai S; Yokomizo A; Morizane S; Kimura T; Shimazui T; Miyauchi Y; Mitsuzuka K; Hara H; Yoshimura K; Shiina H; Ito YM; Murai S; Nishiyama H; Shinohara N; Kitamura H;
Urol Oncol; 2023 Nov; 41(11):458.e9-458.e19. PubMed ID: 37798145
[TBL] [Abstract][Full Text] [Related]
8. Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.
Kudo M; Kang YK; Park JW; Qin S; Inaba Y; Assenat E; Umeyama Y; Lechuga MJ; Valota O; Fujii Y; Martini JF; Williams JA; Obi S
Liver Cancer; 2018 May; 7(2):148-164. PubMed ID: 29888205
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.
Honma N; Inoue T; Tsuchiya N; Koizumi A; Yamamoto R; Nara T; Kanda S; Huang M; Numakura K; Saito M; Narita S; Satoh S; Habuchi T
Health Sci Rep; 2020 Dec; 3(4):e197. PubMed ID: 33088925
[TBL] [Abstract][Full Text] [Related]
10. Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
Narayan V; Haas NB
Int J Nephrol Renovasc Dis; 2016; 9():65-72. PubMed ID: 27099525
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.
Iacovelli R; Santini D; Rizzo M; Felici A; Santoni M; Verzoni E; Masini C; Massari F; Calvani N; Mosca A; Procopio G
Can Urol Assoc J; 2015; 9(7-8):263-7. PubMed ID: 26316911
[TBL] [Abstract][Full Text] [Related]
12. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.
Tomita Y; Fukasawa S; Oya M; Uemura H; Shinohara N; Habuchi T; Rini BI; Chen Y; Bair AH; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2016 Nov; 46(11):1031-1041. PubMed ID: 27572087
[TBL] [Abstract][Full Text] [Related]
13. Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.
Sun M; Larcher A; Karakiewicz PI
Int J Nephrol Renovasc Dis; 2014; 7():401-7. PubMed ID: 25378943
[TBL] [Abstract][Full Text] [Related]
14. Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.
Socola F; Loaiza-Bonilla A; Benedetto P
Case Rep Oncol Med; 2012; 2012():390702. PubMed ID: 23326741
[TBL] [Abstract][Full Text] [Related]
15. Longer recurrence-free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus.
Satoh T; Koie T; Horiguchi H; Tokui N; Narita S; Ohyama C
Clin Case Rep; 2017 Dec; 5(12):1950-1953. PubMed ID: 29225833
[TBL] [Abstract][Full Text] [Related]
16. The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.
Shafrin J; Sullivan J; Chou JW; Neely MN; Doan JF; Maclean JR
Cancer Manag Res; 2017; 9():731-739. PubMed ID: 29238223
[TBL] [Abstract][Full Text] [Related]
17. Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers.
Aguilar K; Sharma AK; Yang T; Mehta D; Panda CS; Lokeshwar VB
J Cell Signal; 2024; 5(2):51-56. PubMed ID: 38726221
[TBL] [Abstract][Full Text] [Related]
18. Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score.
Schmidinger M; Porta C; Oudard S; Denechere G; Brault Y; Serfass L; Costa N; Larkin J
Clin Genitourin Cancer; 2020 Oct; 18(5):e588-e597. PubMed ID: 32586677
[TBL] [Abstract][Full Text] [Related]
19. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Motzer RJ; Robbins PB; Powles T; Albiges L; Haanen JB; Larkin J; Mu XJ; Ching KA; Uemura M; Pal SK; Alekseev B; Gravis G; Campbell MT; Penkov K; Lee JL; Hariharan S; Wang X; Zhang W; Wang J; Chudnovsky A; di Pietro A; Donahue AC; Choueiri TK
Nat Med; 2020 Nov; 26(11):1733-1741. PubMed ID: 32895571
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.
Moran M; Nickens D; Adcock K; Bennetts M; Desscan A; Charnley N; Fife K
Target Oncol; 2019 Aug; 14(4):405-416. PubMed ID: 31301015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
